Billiontoone (NASDAQ:BLLN) Given New $130.00 Price Target at BTIG Research

Billiontoone (NASDAQ:BLLN) had its price objective lowered by stock analysts at BTIG Research from $142.00 to $130.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price target suggests a potential downside of 13.32% from the stock’s current price.

A number of other equities analysts have also weighed in on the company. JPMorgan Chase & Co. upped their target price on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Finally, Guggenheim started coverage on shares of Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Billiontoone Stock Up 5.4%

BLLN opened at $149.97 on Thursday. The firm has a market capitalization of $6.90 billion and a P/E ratio of 272.67. Billiontoone has a one year low of $61.96 and a one year high of $150.44. The company has a fifty day moving average price of $116.73 and a 200-day moving average price of $94.26. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.15. The business had revenue of $109.45 million during the quarter. Equities research analysts expect that Billiontoone will post 0.92 earnings per share for the current fiscal year.

Insider Transactions at Billiontoone

In other Billiontoone news, CTO David Tsao sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $102.27, for a total transaction of $2,045,400.00. Following the sale, the chief technology officer owned 1,000 shares in the company, valued at $102,270. This trade represents a 95.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Oguzhan Atay sold 32,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $136.95, for a total value of $4,450,875.00. Following the completion of the transaction, the chief executive officer owned 20,000 shares of the company’s stock, valued at $2,739,000. The trade was a 61.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 202,049 shares of company stock worth $23,496,861 in the last three months. Insiders own 50.22% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Adams Street Partners LLC purchased a new stake in Billiontoone during the 4th quarter valued at $140,063,000. Baillie Gifford & Co. purchased a new position in Billiontoone in the 4th quarter worth about $103,786,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Billiontoone during the fourth quarter valued at approximately $39,717,000. JPMorgan Chase & Co. bought a new stake in shares of Billiontoone in the fourth quarter worth $32,078,000. Finally, Wasatch Advisors LP bought a new position in shares of Billiontoone in the 1st quarter worth approximately $29,179,000.

Key Headlines Impacting Billiontoone

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: BillionToOne reported second-quarter earnings of $0.15 per share, matching analysts’ consensus, on revenue of $109.45 million. The company also reiterated full-year 2026 revenue guidance of $450 million to $465 million, a range that brackets the $453.3 million consensus estimate. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
• Positive Sentiment: The company’s molecular-diagnostics platform and prenatal-testing business remain the central growth drivers. Investors may also be evaluating whether additional clinical applications can expand growth beyond prenatal screening. Does BillionToOne Have Another Major Growth Engine Beyond Prenatal Testing?
• Neutral Sentiment: The quarterly report did not provide a clear earnings-per-share outlook, limiting visibility into profitability for the remainder of 2026. The revenue forecast is essentially consistent with current expectations rather than a material upgrade.
• Negative Sentiment: CEO Oguzhan Atay sold a combined 45,000 shares worth approximately $6.17 million, reducing his ownership substantially. The transactions were made under a pre-arranged Rule 10b5-1 plan, which lessens their significance as a signal of near-term business concerns but may still create investor caution. SEC CEO Sale Filing
• Negative Sentiment: Another insider sold 4,000 shares for about $561,000. Meanwhile, BLLN’s valuation remains demanding, with a price-to-earnings ratio above 270, increasing sensitivity to any growth slowdown or disappointing guidance.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.